Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...

Sitala Bio Ltd. has divulged complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, schizophrenia, atypical hemolytic uremic syndrome, ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

This important work advances our understanding of factors influencing efficacy assessments and biomarker viability for complement-directed gene therapy against age-related macular degeneration. The ...

Temporal expression of factor I (FI) in vitreous humor (VH) and aqueous humor (AH) after PPY988 delivery. (A,B) FI levels (y-axis, ng/mL) in VH were significantly increased at week 36 and 96 ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Max Eddy Max Eddy is a writer who has covered privacy and security — including ...

Abstract: Tomographic synthetic aperture radar (TomoSAR), as a 3-D imaging technique, is widely applied in urban mapping. In our previous work, a multi-master (MM) TomoSAR approach was proposed for ...

Greater understanding of the underlying molecular causes of inflammation in CKD may lead to biomarkers that more accurately predict the risk of CVD than those currently available and may reveal new ...

aSection Pediatric Infectious Diseases, Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, ...

The FDA approved the oral factor D inhibitor danicopan (Voydeya) as an add-on therapy to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH), AstraZeneca announced.